Clinical trial

Investigator-Sponsored Protocol - Continued Use of Ibalizumab

NCT01056393

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-11-01

PhasePHASE2

Study timeline

Study start (unknown)2009-11-01Date precision: month

Registry last updated2018-07-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV Infectionsunresolved

Interventions

ibalizumab 800mg Q2WeeksDRUG

ibalizumab 2000mg Q4WeeksDRUG

Sponsors & collaborators

Kaiser Permanentelead sponsor

TaiMed Biologics Inc.collaborator

Mapped research locations

Los AngelesCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01056393 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.